CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery PlatformAccesswire • 06/08/22
Wall Street Analysts See a 53% Upside in CureVac N.V. (CVAC): Can the Stock Really Move This High?Zacks Investment Research • 05/31/22
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine DevelopmentAccesswire • 05/25/22
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business UpdateAccesswire • 05/25/22
CureVac NV (CVAC) CEO Franz-Werner Haas on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business UpdateAccesswire • 04/28/22
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022Accesswire • 04/22/22
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical StudyAccesswire • 04/21/22
CureVac, GSK ink 'pandemic preparedness' agreement through 2029 with German governmentMarket Watch • 04/11/22
CureVac and GSK Enter into Pandemic Preparedness Contract with German GovernmentAccesswire • 04/11/22
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoVAccesswire • 03/30/22
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)Accesswire • 03/01/22
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSKAccesswire • 02/10/22
dievini and the Federal Republic of Germany Amend Shareholders' Agreement Regarding Investments in CureVac N.V.Accesswire • 01/13/22